ATX-304 + Retatrutide:
Two Metabolic Signals. One Bigger Question.

BLUF // Bottom Line Up Front

ATX-304 and retatrutide approach metabolic regulation from fundamentally different directions.

Retatrutide is an investigational triple receptor agonist targeting GIP, GLP-1 and glucagon receptors. Its Phase 3 program has demonstrated substantial reductions in body weight.

ATX-304 takes another route.

It is an investigational, orally administered small molecule being developed as a dual AMPK and mitochondrial activator. Rather than primarily targeting appetite, its proposed mechanism centers on cellular energy sensing, substrate metabolism and energy expenditure.

And now there is a signal connecting these two worlds.

That distinction matters.

There is currently no established human clinical evidence demonstrating the safety or effectiveness of an ATX-304 + retatrutide combination.

So this is not a stack guide.

It is a research question.

01 // The Story Didn't End With ATX-304

When ProtokolX first examined ATX-304, the compound stood out because it was attempting something very different from conventional incretin pharmacology.

ATX-304 — previously known as O304 — is not another GLP-1 receptor agonist. It is a peripherally restricted small molecule being investigated as a dual AMPK and mitochondrial activator.

AMP-activated protein kinase — AMPK — functions as one of the body's major cellular energy sensors.

When cellular energy availability falls, AMPK signaling helps coordinate processes involving glucose utilization, lipid metabolism and energy production.

ATX-304 attempts to influence that machinery pharmacologically.

That is intriguing.

But it is equally important to understand what the study did not establish.

Twenty-three participants do not establish ATX-304 as a proven obesity treatment. Larger studies are needed to determine whether these metabolic changes translate into clinically meaningful and durable weight loss.

A metabolic signal is evidence worth following. It is not permission to skip the evidence still missing.

02 // Retatrutide Changed the Other Side of the Equation

While ATX-304 remains early in clinical development, retatrutide has moved deep into human testing.

Retatrutide simultaneously activates three receptors:

The Phase 3 TRIUMPH program has now demonstrated the magnitude of that approach.

TRIUMPH-2 subsequently examined adults with obesity and type 2 diabetes. The peer-reviewed Phase 3 trial included 1,152 randomized participants.

At week 80, the published treatment-regimen estimand showed mean weight changes of approximately:

• -11.9% with 4 mg
• -16.8% with 9 mg
• -18.8% with 12 mg
• -5.1% with placebo

Lilly has separately reported a 20.8% reduction for the 12 mg group using the efficacy estimate. The difference reflects the statistical estimand used rather than conflicting trial results.

Retatrutide has produced substantial Phase 3 human weight-loss data. And that creates the question at the center of this Intelligence Brief.

03 // Two Different Metabolic Levers

That question mark is intentional.

Calling these mechanisms complementary is biologically plausible. Calling the combination clinically synergistic would currently go beyond the evidence.

04 // We Already Have a Clue

Researchers have already tested ATX-304 alongside an incretin. Again, that incretin was semaglutide.

In a diet-induced obesity mouse model, ATX-304 alone produced approximately 21% weight loss after 28 days.

When ATX-304 was combined with lower- or higher-dose semaglutide, both combination groups reached approximately 27% weight reduction after 15 days. At that same point, the corresponding semaglutide-only groups had lost approximately 14% and 19%.

The response in the combination groups was large enough that investigators reduced semaglutide exposure to 10% of its starting dose.

That observation suggests ATX-304 may be doing something fundamentally different from simply suppressing appetite. And that changes the research question.

05 // The Lean-Mass Signal

Body weight is not synonymous with body fat. Any intervention capable of producing large reductions in total weight raises an important question: What tissue is actually being lost?

In the ATX-304 mouse experiments, body-composition measurements indicated that weight reduction in the ATX-304 and ATX-304 + semaglutide groups was attributable to fat mass without a measured reduction in lean mass.

A second experiment pushed the question further. Animals first received semaglutide for 28 days and lost both fat and lean mass. Semaglutide was then withdrawn. Food intake increased. ATX-304 was introduced for another 14 days.

Investigators reported a dose-dependent reduction in weight regain. At the highest exposure, animals continued losing weight relative to baseline without additional loss of lean mass.

Verify, then trust.

06 // The Weight-Regain Question May Be Bigger

The headline surrounding modern incretin therapy is usually how much weight can be lost. The longer-term question may be more difficult:

In the ATX-304 animal study, withdrawal of semaglutide produced hyperphagia and weight regain. ATX-304 altered that trajectory.

Researchers reported dose-dependent prevention of weight regain after semaglutide withdrawal. At the highest tested ATX-304 exposure, animals continued losing weight compared with their original baseline.

That model has not been demonstrated clinically. But ATX-304 gives researchers a pharmacological mechanism with which to test the idea.

07 // Now Insert Retatrutide

This is the point where evidence ends and the ProtokolX hypothesis begins.

Retatrutide is not semaglutide. Semaglutide primarily targets the GLP-1 receptor. Retatrutide activates:

The glucagon component is particularly important to this discussion because glucagon signaling also participates in systemic energy metabolism.

Therefore, combining ATX-304 with retatrutide would not simply recreate the semaglutide experiment using a more powerful weight-loss drug. The biological system would become more complicated.

Potential interactions could involve appetite and satiety, energy expenditure, glucose metabolism, lipid metabolism, hepatic metabolism, body composition, resting metabolic rate, and compensatory responses to substantial weight reduction.

Those interactions could be beneficial, neutral or problematic. We do not know yet.

08 // The Synergy Hypothesis

Strip the idea down to its simplest form and the theoretical architecture looks like this:

It is an attractive model. But biological systems are not simple equations.

Increasing one pathway can trigger compensation elsewhere. Large changes in body mass alter energy requirements. Hormonal adaptation can change hunger. Different organs may respond differently to the same metabolic signal.

And combining two metabolically active investigational agents creates safety questions that monotherapy studies cannot answer.

09 // SIGNAL CHECK

10 // What Would We Want to See Next?

1. ATX-304 + incretin human trials

Does the preclinical complementary effect translate into humans?

2. Direct body-composition measurement

DEXA or MRI-based studies could determine whether fat and lean tissue respond differently during combination treatment.

3. Energy-expenditure studies

Does the Phase 1b resting-metabolic-rate signal persist during substantial weight loss?

4. Withdrawal studies

Could ATX-304 meaningfully alter the trajectory after an incretin is reduced or discontinued?

5. Next-generation incretin combinations

Would the interaction seen with semaglutide persist with dual agonists or a triple agonist such as retatrutide?

11 // The Bigger Picture

The first generation of modern metabolic drugs demonstrated that targeting a single hormonal pathway could meaningfully change body weight. The next generation expanded the number of signals.

GLP-1 became GLP-1 + GIP. Now retatrutide adds glucagon.

ATX-304 proposes something different again. Instead of adding another appetite-related receptor to the equation, it moves downstream toward the machinery responsible for cellular energy sensing and mitochondrial metabolism.

Retatrutide provides one of the strongest hormonal signals currently being investigated for obesity. ATX-304 approaches metabolism from another direction.

Putting them together is scientifically intriguing. For now, however, it remains exactly that: a hypothesis.

The ATX-304 + semaglutide experiments provide the first clue that the concept deserves investigation. Human trials will have to tell us whether the signal survives translation.

PROTOKOL X // FINAL ASSESSMENT

That is where the evidence stands today.

No hype.

No extrapolation disguised as fact.

Just the signal — and the questions that come next.

References & Evidence Trail

1. Schneider EJ, Hall JA, Bor G, et al. Weight Loss and Change in Body Composition in a DIO Mouse Model by the Combined AMPK and Mitochondrial Activator, ATX-304, Alone, in Combination With Semaglutide, and After Semaglutide Withdrawal. Journal of the Endocrine Society. 2025;9(Suppl 1):bvaf149.080.
2. Thieroff-Ekerdt RI, Jacobs D, Hall J, et al. Phase 1b Study of AMPK/Mitochondrial Activator ATX-304 in Prediabetic Obese Participants. Diabetes. 2026;75(Supplement 1):1782-P. doi:10.2337/db26-1782-P.
3. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. 2026;408(10563):1455-1472. doi:10.1016/S0140-6736(26)01861-1.
4. Eli Lilly and Company. TRIUMPH-1 Phase 3 topline results. May 21, 2026.